Breaking News

CureVac to Ramp Up Mfg. of COVID-19 Vax Candidate CVnCoV

Will partner with CDMOs to increase manufacturing capacities for CVnCoV to up to 300 million doses in 2021 and up to 600 million doses in 2022.

By: Contract Pharma

Contract Pharma Staff

CureVac N.V., a biopharmaceutical company developing a new class of medicines based on messenger ribonucleic acid (mRNA), is accelerating the expansion of its manufacturing network to deliver pandemic-scale volumes of its COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production and required technology transfers are underway. The company plans to build a broad and integrated European vaccine manufacturing network with CDMO partners for each of the key manufacturing steps f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters